2024-SABCS-Takeaways - 17

 Incretin Mimetics
Looking Ahead
» The RENAISSANCE trial is comparing
escalating doses of 5 mg, 10 mg, and 20 mg
tamoxifen for chemoprevention, using breast
density as a surrogate marker over 18 months.
CLICK TO EXPAND
same study found that
lower levels of physical
activity were associated
with higher all-cause
mortality and higher
breast cancer-specific
mortality, resulting in a
significantly increased
risk of all-cause mortality
and breast cancerspecific
for Black
Americans. Neighborhood
disadvantage can explain
more than half of the
overall survival difference.
Observational and
preclinical evidence
suggest that GLP-1
receptor agonists and
other incretin mimetics
(topic 2) may reduce
the incidence of obesityassociated
cancers,
including breast cancer,
but long term prospective
evidence is still lacking.
Physical exercise added
to caloric restriction or
bariatric surgery does
not significantly affect
weight loss or body
composition but does
enhance fitness. Current
consensus statements
from the American
College of Sports
Medicine recommend the
combination of physical
activity and anti-obesity
medications to enhance
cardiorespiratory fitness,
muscle strength and
function, and other effects
to extend benefits beyond
body weight or body
composition.
See Incretin Mimetics
above 
A mobile screening
program (PS10-08) in 23
largely rural Appalachian
counties of Tennessee
conducted more than
48,000 screening
mammograms between
2008 and 2023 for more
than 20,000 unique
women. Slightly more than
half of the women (54.5%)
had a single mammogram,
and the remainder had
2-16 mammograms.
Of the breast cancers
diagnosed by the mobile
mammography unit, 80%
were at stage 0 or 1. 
December 10-13, 2024 | San Antonio, Texas
» The phase III BRCA-P breast cancer prevention
study is recruiting BRCA1 carriers aged 25-55
with no previous history of breast cancer at
centers in Austria, Australia, Germany, Israel,
Spain, the U.K., and the U.S. The trial will
compare denosumab to placebo in BRCA1
mutation carriers to assess differences in breast
cancer events.
» The Societal, Ancestry, Molecular and
Biological Analyses of Inequalities (SAMBAI)
project, led by Melissa B. Davis, PhD (at
right), Director, Institute for
Translational Genomic Medicine
at Morehouse School of
Medicine, explores factors that
cause and influence disparate
cancer outcomes in the
African diaspora. Work groups
will focus on the social and
societal determinants, exposures/exposomics,
genomics/epigenomics, tumor immunology and
host immune response, and patient-centered
dissemination practices.
ON USING THE MINIMALLY EFFECTIVE DOSE
" For cancer prevention,
we need to look for the
minimally effective
dose rather than the
maximal tolerated
dose, as our colleagues
do in the therapeutic world. "
SEEMA A. KHAN, MD,
Professor of Surgery and Bluhm
Family Professor of Cancer Research,
Northwestern University
17

https://events.hubilo.com/sabcs2024/session/252210 https://events.hubilo.com/sabcs2024/session/252210 https://events.hubilo.com/sabcs2024/session/252181 https://events.hubilo.com/sabcs2024/session/252181 https://events.hubilo.com/sabcs2024/session/252181

2024-SABCS-Takeaways

Table of Contents for the Digital Edition of 2024-SABCS-Takeaways